This is a great opportunity to enhance your knowledge and experience in a highly competitive biotechnology industry….From Biolegend – Thu, 25 May 2017 02:28:45 GMT – View all San Diego, CA jobs
We are seeking a highly driven, hands on candidate who have a minimum of 5 years of sales experience, a minimum bachelor’s degree in a field relevant to the…
From Indeed – Thu, 25 May 2017 00:53:10 GMT – View all San Diego, CA jobs
The Oncology department provides all aspects of medical monitoring for oncology trials both in partnership with sponsor physicians and independently as needed….From Covance – Wed, 24 May 2017 22:34:54 GMT – View all San Diego, CA jobs
PACIFIC TRANS ENVIRONMENTAL SERVICES, INC. is a leading hazardous waste transporter in East County with a great opportunity for a Field Chemist. This position is responsible for sampling waste streams, developing chemical profiles, writing and review […
Minimum of 1 year pharmaceutical, biotechnology, CRO or Clinical Site supporting clinical research experience required….From Intercept Pharmaceuticals – Wed, 24 May 2017 21:23:04 GMT – View all San Diego, CA jobs
Halozyme Therapeutics Announces Completion Of Public Offering And Full Exercise Of Underwriters’ Option To Purchase Additional Shares
SAN DIEGO, May 24, 2017 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today the completion of its previously announced underwritten public offering of 11,500,000 shares of its common stock. The offering included 1,500,000 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares. All shares in the offering were sold by Halozyme at a public offering price of $12.50 per share. Net proceeds from the offering, after deducting underwriting discounts and commissions and estimated offering expenses, were approximately $135 million.
Halozyme intends to use the net proceeds from this offering to fund continued development of its PEGPH20 oncology program and for other general corporate purposes.
Wells Fargo Securities, LLC and Deutsche Bank Securities acted as joint book-running managers for the offering. Barclays and JMP Securities acted as co-managers for the offering.
An automatic shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the “SEC”) and is effective. A final prospectus supplement and accompanying prospectus relating to this offering have been filed with the SEC. Copies of the final prospectus supplement and accompanying prospectus may be obtained from Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 375 Park Avenue, New York, New York 10152, or by telephone at (800) 326-5897 or email to firstname.lastname@example.org; or Deutsche Bank Securities Inc., Attention: Prospectus Group, 60 Wall Street, New York, NY 10005, or by telephone at (800) 503-4611 or email to email@example.com. Electronic copies of the final prospectus supplement and accompanying prospectus are also available on the website of the SEC at www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment.
Safe Harbor Statement
All of the statements in this press release that are not statements of historical facts constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of such statements include Halozyme’s intended use of proceeds. These statements are based upon management’s current plans and expectations and are subject to a number of risks and uncertainties which could cause actual results to differ materially from such statements. A discussion of the risks and uncertainties that can affect these statements is set forth in Halozyme’s prospectus supplement and the accompanying prospectus filed with the SEC on May 19, 2017, together with the information incorporated by reference, under the heading “Risk Factors.” Halozyme disclaims any intention or obligation to revise or update any forward-looking statements, whether as a result of new information, future events, or otherwise.
SOURCE Halozyme Therapeutics, Inc.
Job Summary: Hologic is seeking a Production Chemist in San Diego, CA. Hologic, Inc. is a leading developer, manufacturer, and supplier of premium molecular diagnostic products and services that are used to diagnose human diseases, screen donated hum […
Create and maintain analyses, tables/listings/figures Perform programming validation and ensures all Quality Control efforts have been followed Provide guidance…From Retrophin – Wed, 24 May 2017 17:13:41 GMT – View all San Diego, CA jobs
A full-time position for a research technician is immediately available in the Division of Vaccine Discovery at the La Jolla Institute for Allergy and Immunology. The research goals of the laboratory are to elucidate the immunobiology o […
SAN FRANCISCO, May 24, 2017 /PRNewswire/ — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Denise Bevers, Co-Founder and COO, will be presenting and hosting one-on-one investor meetings at the 7th Annual LD Micro Invitational in Los Angeles, CA on Tuesday, June 6, 2017 at 1:30 PM PST. The conference will be held at the Luxe Sunset Bel Air Hotel.
Following the presentation, the slide deck will be available for 30 days on the Company’s website: http://kindredbio.com/investor-relations/events.
About Kindred Biosciences, Inc.
Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.
SOURCE Kindred Biosciences, Inc.